Diabetes News

This pleotropic effect of sitagliptin may explain the reduction in postprandial lipemia seen in clinical trials of this agent and may provide metabolic benefits beyond glucose lowering (Diabetes)

https://investor.lilly.com/releasedetail.cfm?ReleaseID=828056

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes1 – press release (Janssen)

Why is once weekly inferior to once daily? (The Lancet Diabetes & Endocrinology)

A definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated (Diabetes Research and Clinical Practice)

Lixisenatide thereby accelerates glucose disposal to nearly physiological intensity, and does not impair counter-regulation to low glucose levels by glucagon (Diabetes, Obesity and Metabolism)

In this 4-week study in patients with T2DM inadequately controlled with metformin monotherapy, saxagliptin added to metformin XR demonstrated a trend for improvement in measures of daily glycemic control, with fewer gastrointestinal adverse events, compared with uptitrated metformin (Diabetes Therapy)

GLP-1RAs provide superior glycaemic control and weight loss vs. DPP-4 inhibitors in patients with T2D. DPP-4 inhibitors may sometimes be preferred to a GLP-1RA if weight is not a concern, oral administration is a desirable feature or when a GLP-1RA cannot be tolerated (International Journal of Clinical Practice)

BIAsp 30 added to OAD therapy results in a better glycaemic control as compared with IGlar in T2DM patients. BIAsp 30 use is associated with slightly larger weight gain but no rise in risk of severe hypoglycaemic episodes (International Journal of Clinical Practice)

It is possible to achieve similar glycemic control with once-daily injection and lower doses of insulin degludec in patients with T1DM who have been treated with insulin glargine or detemir (Diabetes Therapy)

Once-daily lixisenatide significantly improved glycemic control, with a pronounced postprandial effect, without significant increase in symptomatic/severe hypoglycemia risk and with weight loss over 24 weeks (Diabetes and Its Complications)

Even after long duration of diabetes, addition of glimepiride to insulin and metformin can be effective in lowering HbA1c and/or reducing the need for exogenous insulin (Diabetes Research and Clinical Practice)

This is the first study to report a significant association between statin use and diminished amputation risk among patients with diabetes (Journal of Vascular Surgery)

AstraZeneca and Bristol-Myers Squibb today announced that Xigduo™ (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (AstraZeneca)

Withdrawal of rosiglitazone was associated with worsening glucose control and subsequent intensification of treatment regimen (Diabetes and Its Complications)

Despite (in fact because of) the widespread use of insulin analogues it remains critical to analyse the pharmacodynamics (PD) of basal insulin formulations appropriately to interpret the results of clinical trials correctly. Importantly, these data may help physicians in tailoring insulin therapy to patients’ individual needs and, additionally, when clinical evidence is not available, to optimise insulin treatment (Diabetes, Obesity and Metabolism)

Treatment with a Tianqi capsule for 12 months significantly decreased the incidence of T2DM in subjects with IGT, and this herbal drug was safe to use (Journal of Clinical Endocrinology & Metabolism)

Our data suggest that treatment with saxagliptin for 6 weeks normalizes retinal capillary flow and improves central hemodynamics in type-2 diabetes (Cardiovascular Diabetology)

Short-term treatment with ALO/PIO or ALO improved glycemic control in well-controlled T2DM patients, but only combined ALO/PIO improved beta-cell function. These data support that initial combination therapy with a DPP-4 inhibitor and TZD to address multiple core defects in T2DM may be a sensible approach (European Journal of Endocrinology)

Despite the fact that higher statin doses are more likely to lead to new-onset diabetes, for every case of diabetes caused, there are approximately three cardiovascular events reduced with high dose vs. moderate dose statin therapy. Overall, the small risk of developing type 2 diabetes with statin therapy is far outweighed by the potential of statins to decrease cardiac events (Diabetes, Obesity and Metabolism)